Feature | August 23, 2013

Peripheral Artery Disease-Related Amputations Are Costly For Hospitals, Economy and Patients

The Sage Group research looks at these costs of amputation

August 23, 2013 — At the opening session of the third annual Amputation Prevention Symposium (AMP) in Chicago, Mary L. Yost, president of The Sage Group, delivered a lecture titled “Amputation Is It Really Cost-Effective.”

 “Amputation for critical limb ischemia (CLI) is not cost-effective,” said Yost. “The most recent cost-effectiveness analysis demonstrated that amputation was less cost-effective than either surgical or endovascular revascularization.

“Despite being less cost-effective than revascularization, 65,000-70,000 major amputations (above-the-knee and below-the-knee) are performed annually for CLI. The annual cost exceeds $10 billion. Medicare and Medicaid pay almost 80 percent of the bill.

“Published research, as well as our own analysis, demonstrates that amputation actually costs the hospital more than either surgical bypass or endovascular revascularization. Although initial procedure costs are similar, total amputation costs including the costs of in-hospital mortality, morbidity and revision procedures are higher than those of either bypass or endovascular.”

With regard to patient costs associated with amputation, Yost said, “These costs are significant and include lost wages of the patient and family caregiver, copayments and deductibles and modifications for disabled living such as handrails, wheelchair ramps and wheelchair accessible transportation.”

“The costs are not just monetary. Major amputation is frequently a tragedy for patients and their families. In-hospital morbidity and mortality is high. Above-knee and below-knee amputations are two of the top five surgical procedures with the highest perioperative mortality,” she explained.

Commenting on post-discharge patient outcomes Yost said, “For those surviving the procedure, outcomes and quality of life after amputation are dismal. Most amputees undergo a lengthy healing process, 35 percent experience depression, and almost all suffer from chronic pain as well as perceive themselves to be severely physically impaired. Sixty to 80 percent cannot walk; contralateral amputation occurs in 36-50 percent and at two years mortality is 30-50 percent.”

Peripheral artery disease (PAD), also known as peripheral vascular disease (PVD) is characterized by a reduction of blood flow to the lower limbs due to atherosclerosis. In CLI, the most severe and deadly form of PAD, blood flow is so inadequate that rest pain, ulcerations or gangrene occur. Within five years, approximately 70 percent of CLI patients die. This mortality rate exceeds that of coronary artery disease, breast cancer and colorectal cancer.

For more information: www.thesagegroup.us

 

Related Content

ICDs, non-ischemic cardiomyopathy, University of Alabama at Birmingham study, Circulation
News | Implantable Cardioverter Defibrillators (ICD)| January 18, 2017
A new study published in Circulation has found there is a 23 percent risk in reduction of all-cause mortality in non-...
stress, brain activity, cardiovascular risk, PET-CT, MGH, ISSMS, The Lancet study
News | Cardiac Diagnostics| January 18, 2017
A study led by Massachusetts General Hospital (MGH) and Icahn School of Medicine at Mount Sinai (ISSMS) investigators...
ICDs, implantable cardioverter defibrillators, survival rate, elderly patients, JACC study
News | Implantable Cardioverter Defibrillators (ICD)| January 17, 2017
Of patients over age 65 who received an implantable cardioverter-defibrillator (ICD) after surviving sudden cardiac...
University of Utah, Frank Sachse, heart failure, LVAD implantation, left ventricular assist device, biomarker, t-system

Two patients may seem equally sick based upon clinical measures, but differences in their heart physiology could predict who has the potential to recover from heart failure. A study carried out by scientists at the University of Utah finds that patients whose hearts have flattened t-tubules have a decreased chance of showing signs of recovery after implanting a mechanical heart pump. Ordinarily, t-tubules in the heart are long, thin, and rounded. Image courtesy of Frank Sachse.

News | Cardiac Diagnostics| January 17, 2017
Investigators at the University of Utah have identified distinct differences in the hearts of advanced heart failure...
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
St. Jude Medical, Amplatzer Amulet LAA Occluder, observational study, TCT 2016
News | Left Atrial Appendage (LAA) Occluders| November 03, 2016
St. Jude Medical Inc. presented favorable results from the largest observational study to date of the company’s...
Medtronic, CoreValve Evolut R TAVR system, U.S. IDE Study, TCT 2016
News | Heart Valve Technology| November 03, 2016
Medtronic plc unveiled new clinical data showing that patients treated with the self-expanding CoreValve Evolut R...
congenital heart patients, cardiac cath lab, anesthesia sedation practices, joint document, SCAI, SPA, CCAS
News | Congenital Heart| November 03, 2016
The Society for Cardiovascular Angiography and Interventions (SCAI), the Society for Pediatric Anesthesia (SPA) and the...
open-heart surgery, PCI, percutaneous coronary intervention, NOBLE trial, left main coronary artery disease, LMCAD, TCT 2016
News | Cardiovascular Surgery| November 03, 2016
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main...
SENTINEL trial, transcatheter embolic protection, TCEP, TAVR, stroke, TCT 2016
News | Embolic Protection Devices| November 03, 2016
An international study has found that transcatheter cerebral embolic protection (TCEP) is safe, provides effective...
Overlay Init